<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://scemsprotocols.com/scems/index.php?action=history&amp;feed=atom&amp;title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia</id>
	<title>Acute Cardiogenic Pulmonary Edema Pneumonia - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://scemsprotocols.com/scems/index.php?action=history&amp;feed=atom&amp;title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia"/>
	<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;action=history"/>
	<updated>2026-04-05T06:25:22Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.0</generator>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1521&amp;oldid=prev</id>
		<title>Treloars at 14:32, 24 April 2020</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1521&amp;oldid=prev"/>
		<updated>2020-04-24T14:32:23Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 14:32, 24 April 2020&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l4&quot;&gt;Line 4:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 4:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Initial Medical Assessment and Care|INITIAL MEDICAL CARE]] (2.01) - [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Medical Gases&lt;/del&gt;|OXYGEN]] @ 100% via NRB mask or assist with [[Continuous Positive Airway Pressure Device|CPAP]] device in the patient with severe dyspnea.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Initial Medical Assessment and Care|INITIAL MEDICAL CARE]] (2.01) - [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Oxygen&lt;/ins&gt;|OXYGEN]] @ 100% via NRB mask or assist with [[Continuous Positive Airway Pressure Device|CPAP]] device in the patient with severe dyspnea.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1471&amp;oldid=prev</id>
		<title>Treloars at 13:05, 24 April 2020</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1471&amp;oldid=prev"/>
		<updated>2020-04-24T13:05:33Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 13:05, 24 April 2020&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l14&quot;&gt;Line 14:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 14:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Nitro is contraindicated if pt states use of Viagra, Levitra or Cialis (or any ED class of drugs) in the past 24-36 hours. (Document as a pertinent negative).&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Nitro is contraindicated if pt states use of Viagra, Levitra or Cialis (or any ED class of drugs) in the past 24-36 hours. (Document as a pertinent negative).&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, [[Nitro_Drip|NITROGLYCERIN DRIP]] (25 mg in 500cc). Start at 5-15 mcg / minute via Infusion Regulator (“Dial a Flow” device) or Buretrol set. Increase by 5 mcg/min increments. Consider second IV of NaCl, however keep in mind the patient may be a candidate for Fibrinolytics. Monitor and document BP every 5 minutes.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, [[Nitro_Drip|NITROGLYCERIN DRIP]] (25 mg in 500cc). Start at 5-15 mcg / minute via Infusion Regulator (“Dial a Flow” device) or Buretrol set. Increase by 5 mcg/min increments. Consider second IV of NaCl, however keep in mind the patient may be a candidate for Fibrinolytics. Monitor and document BP every 5 minutes.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 90 mm Hg, [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Diuretics&lt;/del&gt;|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 90 mm Hg, [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Lasix&lt;/ins&gt;|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110mm HG and patient has not improved or the patient is anxious consider [[Morphine_Sulfate|MORPHINE SULFATE]] (2.04) refer to [[Analgesia and Sedation|ANALGESIA/SEDATION PRACTICE PARAMETERS]] (2.04).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110mm HG and patient has not improved or the patient is anxious consider [[Morphine_Sulfate|MORPHINE SULFATE]] (2.04) refer to [[Analgesia and Sedation|ANALGESIA/SEDATION PRACTICE PARAMETERS]] (2.04).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1454&amp;oldid=prev</id>
		<title>Treloars at 12:49, 24 April 2020</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1454&amp;oldid=prev"/>
		<updated>2020-04-24T12:49:14Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 12:49, 24 April 2020&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l9&quot;&gt;Line 9:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 9:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If PULSE &amp;lt; 60 and systolic BP &amp;lt; 90 mm Hg, refer to [[Supraventricular Bradycardia and AV Blocks|SUPRAVENTRICULAR BRADYCARDIA AND A.V. BLOCKS PRACTICE PARAMETERS]] (4.06).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If PULSE &amp;lt; 60 and systolic BP &amp;lt; 90 mm Hg, refer to [[Supraventricular Bradycardia and AV Blocks|SUPRAVENTRICULAR BRADYCARDIA AND A.V. BLOCKS PRACTICE PARAMETERS]] (4.06).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If PULSE &amp;gt; 60 and systolic BP &amp;lt; 90 mm Hg, refer to [[Shock|SHOCK PRACTICE PARAMETER]] (5.13).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If PULSE &amp;gt; 60 and systolic BP &amp;lt; 90 mm Hg, refer to [[Shock|SHOCK PRACTICE PARAMETER]] (5.13).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If wheezing present, and pulse rate &amp;lt; 150 administer [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Bronchodilators&lt;/del&gt;|ALBUTEROL (PROVENTIL)]] 2.5 mg via updraft. Monitor heart rate and repeat as necessary or until HR&amp;gt; 150. [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Bronchodilators&lt;/del&gt;|IPRATROPIUM BROMIDE (ATROVENT)]] is contraindicated)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If wheezing present, and pulse rate &amp;lt; 150 administer [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Albuterol&lt;/ins&gt;|ALBUTEROL (PROVENTIL)]] 2.5 mg via updraft. Monitor heart rate and repeat as necessary or until HR&amp;gt; 150. [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Atrovent&lt;/ins&gt;|IPRATROPIUM BROMIDE (ATROVENT)]] is contraindicated)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, and no presence of fever or other signs of pneumonia:&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, and no presence of fever or other signs of pneumonia:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** [[Nitro_Spray|NITROGLYCERIN SPRAY]] OR [[Nitro_Tablets|NITROGLYCERIN TABLET]] 0.4 mg SL (Do not withhold if unable to establish IV). Repeat at 5 minute intervals until systolic BP &amp;lt; 110 mm Hg or [[Nitro_Drip|NITROGLYCERIN DRIP]] established. (Team member shall be assigned as the “nitro-time keeper” and BP monitor)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** [[Nitro_Spray|NITROGLYCERIN SPRAY]] OR [[Nitro_Tablets|NITROGLYCERIN TABLET]] 0.4 mg SL (Do not withhold if unable to establish IV). Repeat at 5 minute intervals until systolic BP &amp;lt; 110 mm Hg or [[Nitro_Drip|NITROGLYCERIN DRIP]] established. (Team member shall be assigned as the “nitro-time keeper” and BP monitor)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1380&amp;oldid=prev</id>
		<title>Treloars at 21:25, 23 April 2020</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1380&amp;oldid=prev"/>
		<updated>2020-04-23T21:25:50Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 21:25, 23 April 2020&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l11&quot;&gt;Line 11:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 11:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If wheezing present, and pulse rate &amp;lt; 150 administer [[Bronchodilators|ALBUTEROL (PROVENTIL)]] 2.5 mg via updraft. Monitor heart rate and repeat as necessary or until HR&amp;gt; 150. [[Bronchodilators|IPRATROPIUM BROMIDE (ATROVENT)]] is contraindicated)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If wheezing present, and pulse rate &amp;lt; 150 administer [[Bronchodilators|ALBUTEROL (PROVENTIL)]] 2.5 mg via updraft. Monitor heart rate and repeat as necessary or until HR&amp;gt; 150. [[Bronchodilators|IPRATROPIUM BROMIDE (ATROVENT)]] is contraindicated)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, and no presence of fever or other signs of pneumonia:&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, and no presence of fever or other signs of pneumonia:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Antianginals&lt;/del&gt;|NITROGLYCERIN]] 0.4 mg SL (Do not withhold if unable to establish IV). Repeat at 5 minute intervals until systolic BP &amp;lt; 110 mm Hg or [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Antianginals&lt;/del&gt;|NITROGLYCERIN DRIP]] established. (Team member shall be assigned as the “nitro-time keeper” and BP monitor)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Nitro_Spray&lt;/ins&gt;|NITROGLYCERIN &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SPRAY]] OR [[Nitro_Tablets|NITROGLYCERIN TABLET&lt;/ins&gt;]] 0.4 mg SL (Do not withhold if unable to establish IV). Repeat at 5 minute intervals until systolic BP &amp;lt; 110 mm Hg or [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Nitro_Drip&lt;/ins&gt;|NITROGLYCERIN DRIP]] established. (Team member shall be assigned as the “nitro-time keeper” and BP monitor)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Nitro is contraindicated if pt states use of Viagra, Levitra or Cialis (or any ED class of drugs) in the past 24-36 hours. (Document as a pertinent negative).&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Nitro is contraindicated if pt states use of Viagra, Levitra or Cialis (or any ED class of drugs) in the past 24-36 hours. (Document as a pertinent negative).&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Antianginals&lt;/del&gt;|NITROGLYCERIN DRIP]] (25 mg in 500cc). Start at 5-15 mcg / minute via Infusion Regulator (“Dial a Flow” device) or Buretrol set. Increase by 5 mcg/min increments. Consider second IV of NaCl, however keep in mind the patient may be a candidate for Fibrinolytics. Monitor and document BP every 5 minutes.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110 mm Hg, [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Nitro_Drip&lt;/ins&gt;|NITROGLYCERIN DRIP]] (25 mg in 500cc). Start at 5-15 mcg / minute via Infusion Regulator (“Dial a Flow” device) or Buretrol set. Increase by 5 mcg/min increments. Consider second IV of NaCl, however keep in mind the patient may be a candidate for Fibrinolytics. Monitor and document BP every 5 minutes.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 90 mm Hg, [[Diuretics|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 90 mm Hg, [[Diuretics|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1338&amp;oldid=prev</id>
		<title>Treloars at 20:19, 22 April 2020</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=1338&amp;oldid=prev"/>
		<updated>2020-04-22T20:19:07Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 20:19, 22 April 2020&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l16&quot;&gt;Line 16:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 16:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 90 mm Hg, [[Diuretics|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 90 mm Hg, [[Diuretics|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110mm HG and patient has not improved or the patient is anxious consider [[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Analgesics&lt;/del&gt;|MORPHINE SULFATE]] (2.04) refer to [[Analgesia and Sedation|ANALGESIA/SEDATION PRACTICE PARAMETERS]] (2.04).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* If systolic BP &amp;gt; 110mm HG and patient has not improved or the patient is anxious consider [[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Morphine_Sulfate&lt;/ins&gt;|MORPHINE SULFATE]] (2.04) refer to [[Analgesia and Sedation|ANALGESIA/SEDATION PRACTICE PARAMETERS]] (2.04).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Cardiac|0411]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Cardiac|0411]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=963&amp;oldid=prev</id>
		<title>Treloars at 15:39, 1 February 2018</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=963&amp;oldid=prev"/>
		<updated>2018-02-01T15:39:47Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 15:39, 1 February 2018&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l20&quot;&gt;Line 20:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 20:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Cardiac]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Cardiac&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|0411&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=328&amp;oldid=prev</id>
		<title>Treloars: /* Section 4 - CARDIAC */</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=328&amp;oldid=prev"/>
		<updated>2012-04-02T00:58:09Z</updated>

		<summary type="html">&lt;p&gt;&lt;span class=&quot;autocomment&quot;&gt;Section 4 - CARDIAC&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 00:58, 2 April 2012&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l19&quot;&gt;Line 19:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 19:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:Cardiac]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=81&amp;oldid=prev</id>
		<title>Treloars: Created page with &quot;==Section 4 - CARDIAC== ===4.11 ACUTE CARDIOGENIC PULMONARY EDEMA===    INITIAL MEDICAL CARE (2.01) - OXYGEN @ 100% v...&quot;</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Acute_Cardiogenic_Pulmonary_Edema_Pneumonia&amp;diff=81&amp;oldid=prev"/>
		<updated>2012-02-02T15:12:25Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Section 4 - CARDIAC== ===4.11 ACUTE CARDIOGENIC PULMONARY EDEMA===    &lt;a href=&quot;/scems/index.php/Initial_Medical_Assessment_and_Care&quot; title=&quot;Initial Medical Assessment and Care&quot;&gt;INITIAL MEDICAL CARE&lt;/a&gt; (2.01) - &lt;a href=&quot;/scems/index.php/Medical_Gases&quot; title=&quot;Medical Gases&quot;&gt;OXYGEN&lt;/a&gt; @ 100% v...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Section 4 - CARDIAC==&lt;br /&gt;
===4.11 ACUTE CARDIOGENIC PULMONARY EDEMA===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Initial Medical Assessment and Care|INITIAL MEDICAL CARE]] (2.01) - [[Medical Gases|OXYGEN]] @ 100% via NRB mask or assist with [[Continuous Positive Airway Pressure Device|CPAP]] device in the patient with severe dyspnea.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* If PULSE &amp;lt; 60 and systolic BP &amp;lt; 90 mm Hg, refer to [[Supraventricular Bradycardia and AV Blocks|SUPRAVENTRICULAR BRADYCARDIA AND A.V. BLOCKS PRACTICE PARAMETERS]] (4.06).&lt;br /&gt;
* If PULSE &amp;gt; 60 and systolic BP &amp;lt; 90 mm Hg, refer to [[Shock|SHOCK PRACTICE PARAMETER]] (5.13).&lt;br /&gt;
* If wheezing present, and pulse rate &amp;lt; 150 administer [[Bronchodilators|ALBUTEROL (PROVENTIL)]] 2.5 mg via updraft. Monitor heart rate and repeat as necessary or until HR&amp;gt; 150. [[Bronchodilators|IPRATROPIUM BROMIDE (ATROVENT)]] is contraindicated)&lt;br /&gt;
* If systolic BP &amp;gt; 110 mm Hg, and no presence of fever or other signs of pneumonia:&lt;br /&gt;
** [[Antianginals|NITROGLYCERIN]] 0.4 mg SL (Do not withhold if unable to establish IV). Repeat at 5 minute intervals until systolic BP &amp;lt; 110 mm Hg or [[Antianginals|NITROGLYCERIN DRIP]] established. (Team member shall be assigned as the “nitro-time keeper” and BP monitor)&lt;br /&gt;
**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Nitro is contraindicated if pt states use of Viagra, Levitra or Cialis (or any ED class of drugs) in the past 24-36 hours. (Document as a pertinent negative).&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* If systolic BP &amp;gt; 110 mm Hg, [[Antianginals|NITROGLYCERIN DRIP]] (25 mg in 500cc). Start at 5-15 mcg / minute via Infusion Regulator (“Dial a Flow” device) or Buretrol set. Increase by 5 mcg/min increments. Consider second IV of NaCl, however keep in mind the patient may be a candidate for Fibrinolytics. Monitor and document BP every 5 minutes.&lt;br /&gt;
* If systolic BP &amp;gt; 90 mm Hg, [[Diuretics|FUROSEMIDE]] 1 mg / kg Slow IVP. (Maximum dosage is 100 mg)&lt;br /&gt;
**&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;NOTE: Furosemide should only be used, when you are sure the patient has CHF. Do not give a diuretic to a dehydrated patient. Check for edematous legs, jugular vein distention, ascites, sacral edema &amp;amp; rales.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* If systolic BP &amp;gt; 110mm HG and patient has not improved or the patient is anxious consider [[Analgesics|MORPHINE SULFATE]] (2.04) refer to [[Analgesia and Sedation|ANALGESIA/SEDATION PRACTICE PARAMETERS]] (2.04).&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;Goal is for a B/P reduction to approximately 120/60 without an increase in pulse. This is for patients with no neurological involvement only.&amp;#039;&amp;#039;&amp;#039;&amp;#039;&amp;#039;&lt;/div&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
</feed>